DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms

DexCom logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • DexCom expects a record number of new patients in 2026 and has raised its outlook to the top of its original range, with U.S. growth led by people with Type 2 diabetes.
  • A CMS decision on broader Medicare coverage for people with Type 2 diabetes is expected before year-end, but even an approval may not reach patients until mid-2027. The expansion remains unapproved.
  • DexCom’s 2030 plan targets annual revenue growth above 10%, gross margins in the high 60% range and operating margins of 29%–30%; the company also plans another $1 billion in share buybacks in 2027.
  • Interested in DexCom? Here are five stocks we like better.

DexCom NASDAQ: DXCM expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferies.

CEO Jake Leach said the company has raised its outlook to the top end of the range issued at the beginning of the year, with growth in the United States driven primarily by people with Type 2 diabetes who use insulin and those who do not use insulin but have insurance coverage for the technology.

DexCom is awaiting a decision from the Centers for Medicare and Medicaid Services on broader coverage for people with Type 2 diabetes. Leach said the company expects to hear back before year-end, although he estimated that reimbursement would not reach patients until mid-2027 if a decision comes by then, because of a comment period and administrative work.

Coverage Expansion and Long-Term Targets

Leach pointed to DexCom’s CONNECT study, published in the New England Journal of Medicine, as evidence supporting broader coverage. He said the study showed improvements in glucose control and A1C over six months among participants with Type 2 diabetes, including those taking a range of glucose-lowering medications and those taking none.

The CEO said the company has had multiple conversations with CMS and has been told the decision is progressing and will be based on evidence. Coverage has not yet been approved.

CFO and COO Jereme Sylvain said DexCom’s long-range plan through 2030 calls for annual revenue growth of more than 10%, gross margin expansion into the high 60% range and operating margin expansion to 29% to 30%. He said the plan assumes 10% to 15% penetration of the Type 2 non-insulin market in its later years, compared with less than 5% entering this year.

Sylvain said DexCom’s operating margin was around 21% last year and is running at 24% this year. He expects continued progress as the company benefits from its 15-day product, operational improvements and more efficient service delivery.

Product and International Strategy

Leach attributed recent U.S. market share gains in part to the rollout of the G7 15-day sensor. He said DexCom is not seeing the slowdown discussed elsewhere in the market, while Sylvain said the company continues to grow despite pricing and product-mix headwinds.

Internationally, Leach said the company sees its largest long-term growth opportunity outside the United States. DexCom plans to play a more active role in securing coverage and establishing a presence in markets as access expands, particularly for people with Type 2 diabetes.

Sylvain said DexCom also plans to take its largest remaining distributor-based business direct in mid-2027. He said direct operations can help the company invest in reaching primary care physicians beyond the specialist-focused channels served by distributors. He did not identify the market during the discussion.

In January 2027, DexCom plans to launch a service called Dexcom Direct to help patients and physicians navigate insurance coverage and reimbursement routes. Leach said difficulty determining how to obtain and pay for a device remains a significant barrier to use.

Next-Generation Sensors and Buybacks

Leach said DexCom’s planned G8 sensor platform is designed to be 50% smaller than G7 and to improve accuracy and reliability. It is also designed to measure multiple substances, although he did not provide launch dates for additional measurements.

The company is developing sensors for potassium, ketones and lactate, Leach said. He described potassium monitoring as a potential opportunity for patients with diabetes and kidney disease.

On capital allocation, Sylvain said DexCom has committed to returning at least half of its growing free cash flow to shareholders. The company has announced plans for another $1 billion in share buybacks in 2027, while continuing to consider investments such as distributor acquisitions and smaller technology purchases.

About DexCom (NASDAQ:DXCM)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company's products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DexCom Right Now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines